ASCO GI 2021 | Phase II trial of neoadjuvant bevacizumab + modified FOLFOX7 in rectal cancer

Afsaneh Barzi, MD, PhD, City of Hope Comprehensive Cancer Center, Duarte, CA, discusses the results of a Phase II trial of neoadjuvant bevacizumab with modified FOLFOX7 in lieu of radiation in patients with stage II and III rectal cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).